Spruce Street Capital LP
Spruce Street Capital LP reported 30 holdings worth US$510M as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 13, 2026
Spruce Street Capital LP reported 30 holdings worth US$510M as of Jun 30, 2026. Largest: Relay Therapeutics, Inc., Lb Pharmaceuticals Inc and Relmada Therapeutics, Inc. Filed Aug 13, 2026 (Form 13F).
- Holdings
- 30
- Value as reported
- US$510M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Relay Therapeutics, Inc. | 2.98M | US$55.8M | 11.0% |
| Lb Pharmaceuticals Inc | 1.38M | US$44.7M | 8.8% |
| Relmada Therapeutics, Inc. | 6.39M | US$44.2M | 8.7% |
| Alto Neuroscience, Inc. | 1.35M | US$35.7M | 7.0% |
| Dianthus Therapeutics, Inc. | 355K | US$34.6M | 6.8% |
| Savara, Inc. | 3.45M | US$21.3M | 4.2% |
| Vaxcyte, Inc. | 306K | US$17.8M | 3.5% |
| Enliven Therapeutics, Inc. | 329K | US$16.7M | 3.3% |
| Enanta Pharmaceuticals, Inc. | 1.09M | US$15.9M | 3.1% |
| Perspective Therapeutics, Inc. | 3.69M | US$12.6M | 2.5% |
| Surrozen, Inc. | 432K | US$11.2M | 2.2% |
| Alumis Inc. | 393K | US$11M | 2.2% |
| Century Therapeutics, Inc. | 4.06M | US$9.94M | 2.0% |
| Minerva Neurosciences, Inc | 1.66M | US$9.19M | 1.8% |
| Sab Biotherapeutics, Inc. | 2.2M | US$8.57M | 1.7% |
| An2 Therapeutics, Inc. | 1.66M | US$8.04M | 1.6% |
| Erasca, Inc. | 423K | US$7.74M | 1.5% |
| Inhibikase Therapeutics, Inc. | 3.58M | US$7.27M | 1.4% |
| Research Alliance Corporation Iii | 500K | US$5.35M | 1.0% |
| Helix Acquisition Corp. Iii | 500K | US$5.32M | 1.0% |
| Zai Lab Ltd. | 279K | US$5.3M | 1.0% |
| Achieve Life Sciences, Inc. | 737K | US$4.81M | 0.94% |
| Lexeo Therapeutics, Inc. | 929K | US$4.32M | 0.85% |
| Alector, Inc. | 2.1M | US$4.22M | 0.83% |
| Leonabio, Inc. | 394K | US$3.62M | 0.71% |
| Corvus Pharmaceuticals, Inc. | 232K | US$3.46M | 0.68% |
| Jatt Ii Acquisition Corp | 160K | US$1.82M | 0.36% |
| Kalvista Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
| Maze Therapeutics, Inc. | 0 | US$0 | 0.00% |
Source
View original at SEC
Related